Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CEP-11981

Known as: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981 
An orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR) and Tie2 receptor tyrosine kinases with potential… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
SummaryBackground This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Peroxiredoxin 1 participates in ischemia‐triggered endothelial polarization
The balance between endothelial cell survival and death plays a pivotal role in brain remodeling and repair after stroke [1… Expand
2014
2014
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma.
BACKGROUND Angiopoietin/Tyrosine Kinase-2 (ANG/TIE2), Fibroblast Growth Factor-1 (FGFR1) and Vascular Endothelial Growth Factor… Expand
2012
2012
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2…
A substantial body of evidence supports the utility of antiangiogenesis inhibitors as a strategy to block or attenuate tumor… Expand
2007
2007
CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models
B264 The identification of novel anti-angiogenic agents with favorable drug-like properties and the ability to induce objective… Expand
2005
2005
Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.
The degree of angiogenesis in breast cancer has previously been shown to be an indicator of prognosis, and tumor microvasculature… Expand
Highly Cited
2003
Highly Cited
2003
Angiopoietin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis
Background—Angiopoietin (Ang)–1 is an angiogenic growth factor that counteracts the permeability and proinflammatory effects of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2003
2003
Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
The degree of angiogenesis in breast cancer has previously been shown to be an indicator of prognosis, and tumor microvasculature… Expand
2003
2003
Results Ang 2 and Tie 2 Immunoreactivity Is Induced in Capillaries and Postcapillary Venules of Cardiac Allografts
Background—Angiopoietin (Ang)–1 is an angiogenic growth factor that counteracts the permeability and proinflammatory effects of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2001
2001
Mechanistic effects of autophosphorylation on receptor tyrosine kinase catalysis: enzymatic characterization of Tie2 and phospho-Tie2.
Activation of receptor tyrosine kinases by autophosphorylation is one of the most common and critical transformations in signal… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE